Premium
Interleukin‐1 inhibition by anakinra in refractory chronic tophaceous gout
Author(s) -
TRAN Ai P.,
EDELMAN Jack
Publication year - 2011
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/j.1756-185x.2011.01629.x
Subject(s) - anakinra , medicine , gout , inflammasome , refractory (planetary science) , pathophysiology , interleukin , gastroenterology , dermatology , inflammation , cytokine , disease , physics , astrobiology
Since the discovery of the inflammasome, interleukin 1 production has been found to be integral in the pathophysiology of gout. Interleukin 1 inhibition by Anakinra has been shown to effective for the treatment of gout. We report three cases of resistant chronic tophaceous gout who responded to anakinra subcutaneous injections on an intermittent basis.